124752-23-4

Basic information

• Product Name: tert-Butyl (4R-cis)-6-formaldehydel-2,2-dimethyl-1,3-dioxane-4-acetate
• Synonyms: TERT-BUTYL (3R,5S)-6-OXO-3,5-O-ISO-PROPYLIDENE-3,5-DIHYDROXYHEXANOATE;(4R-cis)-6-Formaldehydel-2,2-dimethyl-1,3-dioxane-4-acetic acid 1,1-dimethylethyl ester;tert-Butyl (4R-cis)-6-formaldehydel-2,2-dimethyl-1,3-dioxane-4-acetate;(3R,5S)-6-Oxo-3,5-O-diisopropylidene-3,5-dihydroxyhexanoic acid tert-butyl ester;tert-Butyl (4R-cis)-6-ForMaldehydel-2,2-diMethyl-1,3-dioxane-4-acetate DISCONTINUED. See H946660;(4R-Cis)-6-ForMaldehydel-2,2-diMethyl-1,3-dioxane-4-acetic acid,1,1-diMenthylethyl ester;tert-Butyl [(4R, 6S)-6-forMyl-2,2-diMethyl-1,3-dioxan-4-yl]acetate;(4R-cis)-6-forMaldehydel-2,2-diMethyl-1, 3-dioxane
• CAS NO: 124752-23-4
• Molecular Formula: C₁₃H₂₂O₅
• Molecular Weight: 258.31
• EINECS: 1308068-626-2
• Product Categories: Chiral Reagents;Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals;Pharmaceutical intermediates;INTERMEDIATES OF ROSUVASTATIN
• Mol File: 124752-23-4.mol

Chemical Properties

• Boiling Point: 320.344 °C at 760 mmHg
• Flash Point: 140.583 °C
• Appearance: /
• Density: 1.073 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.47
• Storage Temp.: Inert atmosphere,Store in freezer, under -20°C
• CAS DataBase Reference: tert-Butyl (4R-cis)-6-formaldehydel-2,2-dimethyl-1,3-dioxane-4-acetate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-Butyl (4R-cis)-6-formaldehydel-2,2-dimethyl-1,3-dioxane-4-acetate(124752-23-4)
• EPA Substance Registry System: tert-Butyl (4R-cis)-6-formaldehydel-2,2-dimethyl-1,3-dioxane-4-acetate(124752-23-4)

Safety Data

• Hazardous Substances Data: 124752-23-4(Hazardous Substances Data)

Usage

Uses

tert-Butyl (4R-cis)-6-formaldehydel-2,2-dimethyl-1,3-dioxane-4-acetate can be used as intermediate used in the synthesis of statins.

InChI:InChI=1/C13H22O5/c1-12(2,3)18-11(15)7-9-6-10(8-14)17-13(4,5)16-9/h8-10H,6-7H2,1-5H3/t9-,10+/m1/s1

Upstream product

• 124655-09-0 1,1-dimethylethyl (4R-cis)-6-hydroxymethyl-2,2-dimethyl-1,3-dioxane-4-acetate 
• 147489-02-9 isopropyl (2S,3R,4S,6R)-7-t-butoxycarbonyl-2,3-dihydroxy-4,6-isopropylidenedioxyheptanoate 
• 147489-00-7 isopropyl (2S,3R,4S,6R)-7-t-butoxycarbonyl-2,3-bis(t-butyldimethylsilyloxy)-4,6-dihydroxyheptanoate 
• 147489-01-8 isopropyl (2S,3R,4S,6R)-7-t-butpxycarbonyl-2,3-bis(t-butyldimethylsilyloxy)-4,6-isopropylidenedioxyheptanoate 
• 147488-99-1 isopropyl (2S,3S,6R)-7-t-butoxycarbonyl-2,3-bis(t-butyldimethylsilyloxy)-6-hydroxy-4-oxoheptanoate 
• 147488-98-0 isopropyl (2S,3S)-7-t-butoxycarbonyl-2,3-bis(t-butyldimethylsilyloxy)-4,6-dioxoheptanoate 
• 1694-31-1 tert-butyl acetoacetate 
• 540-88-5 acetic acid tert-butyl ester 
• 124655-07-8 (3R,5S)-tert-butyl 6-(tert-butyldiphenylsilyloxy)-3,5-dihydroxyhexanoate 
• 124655-06-7 (5S)-6-(tert-butyl-diphenylsilanyloxy)-5-hydroxy-3-oxohexanoic acid tert-butyl ester 
• 124655-08-9 tert-butyl 2-((4R,6S)-6-((tert-butyldiphenylsilyloxy)methyl)-2,2-dimethyl-1,3-dioxan-4-yl)acetate 
• 79-37-8 oxalyl dichloride 
• 406680-96-4 tert-butyl (5S)-6-chloro-3,5-dihydroxyhexanoate 
• 154026-94-5 (4R-cis)-6-(chloromethyl)-2,2-dimethyl-1,3-dioxane-4-acetic acid,1,1-dimethylethyl ester 

Downstream Products

• 129894-42-4 ((4R,6S)-6-{(Z)-2-[4-(4-Fluoro-phenyl)-2-isopropyl-6-phenyl-pyridin-3-yl]-vinyl}-2,2-dimethyl-[1,3]dioxan-4-yl)-acetic acid tert-butyl ester 
• 124655-11-4 ((4R,6S)-6-{(E)-2-[4-(4-Fluoro-phenyl)-2-isopropyl-6-phenyl-pyridin-3-yl]-vinyl}-2,2-dimethyl-[1,3]dioxan-4-yl)-acetic acid tert-butyl ester 
• 147489-06-3 (4R,6S)-(E)-{6-[2-(2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl)-vinyl]-2,2-dimethyl-1,3-dioxan-4-yl}acetic acid tert-butyl ester 
• 124655-09-0 1,1-dimethylethyl (4R-cis)-6-hydroxymethyl-2,2-dimethyl-1,3-dioxane-4-acetate 
• 916314-43-7 tert-butyl 2-((4R,6S)-6-((E)-2-(4-(4-fluorophenyl)-2,6-diisopropyl-5-[(d3-methoxy)methyl]pyridin-3-yl)vinyl)-2,2-dimethyl-1,3-dioxan-4-yl)acetate 
• 289042-12-2 2-[(4R,6S)-6-[(E)-2-[4-(4-fluorophenyl)-2-(N-methylmethanesulfonamido)-6-(isopropyl)pyrimidin-5-yl]vinyl]-2,2-dimethyl-1,3-dioxan-4-yl]acetic acid tert butyl ester 
• 500731-91-9 tert-butyl 2-((4R,6S)-6-((E)-2-(3-(4-fluorophenyl)-1-isopropylindol-2-yl)vinyl)-2,2-dimethyl-1,3-dioxan-4-yl)acetate 
• 917805-74-4 (3R,5S,6E)-7-[4-(4-fluorophenyl)-2-[methyl(methylsulfonyl)amino]-6-(propan-2-yl)pyrimidin-5-yl]-3,5-dihydroxyhept-6-enoic acid-2-methylpropan-2-amine 
• 855249-03-5 (6-{2-[3-(4-fluorophenyl)-1-isopropyl-5-(4-methoxybenzylcarbamoyl)-4-phenyl-1H-pyrrol-2-yl]vinyl}-2,2-dimethyl-[1,3]dioxan-4-yl)acetic acid tert-butyl ester 
• 950524-34-2 C₃₇H₄₅FN₂O₅ 
• 950524-10-4 C₄₀H₄₃FN₂O₅ 
• 950524-18-2 C₄₁H₄₅FN₂O₅ 

Relevant articles and documents

A new way to tert-Butyl [(4R,6R)-6-aminoethyl-2,2-dimethyl-1,3-dioxan-4-yl]acetate, a key intermediate of atorvastatin synthesis

A new synthesis of tert-butyl [(4R,6R)-6-aminoethyl-2,2-dimethyl-1,3-dioxan-4-yl]acetate, a key intermediate of the synthesis of an effective HMG-CoA reductase inhibitor atorvastatin, is described. The synthesis is based on the Henry reaction of nitromethane and tert-butyl [(4R,6S)-6-formyl-2,2-dimethyl-1,3-dioxan-4-yl] acetate. The formed nitroaldol was then O-acetylated and the sodium borohydride reduction of the intermediate provided tert-butyl [(4R,6R)-2,2-dimethyl-6-nitroethyl-1,3-dioxan-4-yl] acetate. Catalytic hydrogenation of the nitro group led to the title compound.

Preparation method of rosuvastatin calcium intermediate

The invention belongs to the technical field of medicinal chemistry and relates to the technical field of drug synthesis, particularly to a preparation method of a high-purity rosuvastatin calcium intermediate. The preparation method of the high-purity rosuvastatin calcium intermediate comprises controlling reaction PH and temperature and applied amount of sodium hypochlorite to control the content of impurities in the high-purity rosuvastatin calcium intermediate shown as the formula I', thereby improving the yield and purity of finished products. The content of impurity compound I' in the high-purity rosuvastatin calcium intermediate prepared through the method is lower than 0.05%. The preparation method of the high-purity rosuvastatin calcium intermediate is highly significant to quality improvement of industrialized production products of the high-purity rosuvastatin calcium intermediate, and further achieves certain assisting and supporting effects on quality improvement as well as registration and declaration of rosuvastatin calcium drugs.

Method for preparing rosuvastatin side chain through oxidation in continuous flow micro-channel reactor

The invention relates to a method for preparing a rosuvastatin side chain through oxidation in a continuous flow micro-channel reactor. In the micro-channel reactor, a compound D6 is oxidized by sodium hypochlorite to synthesize a compound D7; the reaction flow is shown in the specification. The method solves the problems that existing preparation methods are long in reaction time, high in requirements on reaction condition, incapable of continuous product, high in cost and the like. The method has the advantages of simplicity and safety in operation, short reaction time, high product conversion rate, high product purity and the like, materials after reaction can be directly subjected to aftertreatment operation, aftertreatment is simple, the product yield is 92% or above, the product purity is 99.8%, and the method is particularly suitable for industrial large-scale production.

Preparation method of rosuvastatin side chain intermediate

The invention belongs to the technical field of medicines, and particularly provides a preparation method of a rosuvastatin side chain intermediate. The method comprises the following steps: (1) dissolving a compound I, an oxidation catalyst and a phase transfer catalyst in an organic solvent A, respectively adding a buffer solution of alkali and an oxidant, and reacting to obtain a compound II; and (2) dissolving the compound II crude product in an organic solvent B, heating for dissolving, adding purified water, separating out a solid, filtering and drying to obtain a compound II refined product. The yield of the rosuvastatin side chain intermediate prepared by the technology is higher than 95%, the HPLC purity is higher than 99.70%, and the generated carboxylic acid impurity is lower than 0.2%. The method has the advantages of mild reaction conditions, no need of ultralow temperature, no water and other harsh reaction conditions, no foul gas generation in the reaction process, environmental protection, easy amplification generation, easy realization of the reaction temperature, and facilitation of industrial production.

Rosuvastatin calcium intermediate, preparation method thereof and application of intermediate

The invention discloses a rosuvastatin calcium intermediate, a preparation method thereof and an application of the intermediate. The synthesis process of the intermediate is environmentally friendly,simple and convenient to operate and low in EHS (environment health safety) risk, raw materials are easily available, and used chemical reagents are low in toxicity and low in price, so that the synthesis process of the intermediate is a green synthesis process suitable for industrial production. In addition, the intermediate is applied to synthesis of rosuvastatin calcium and key intermediates thereof, has short route and high yield, effectively reduces the industrial production cost of rosuvastatin calcium, and has a higher industrial application prospect.

A method for preparing a rosuvastatin calcium intermediate

The invention relates to the technical field of pharmaceutical chemistry, particularly the field of process optimization and cost control for pharmaceutical intermediate preparation, and more particularly relates to an impurity in preparation of a rosuvastatin calcium intermediate and a method for synthesizing the intermediate from the impurity. A compound I' is reacted with ozone and a reductantto obtain a compound IV and an important intermediate III, the compound IV is further subjected to reduction and substitution to prepare another intermediate II important in preparation of the rosuvastatin calcium intermediate, and the compound II and the compound III are adopted to prepare an intermediate compound I. Through recovery and utilization of the impurity compound I', the preparation cost of the compound I is significantly reduced. The method is simple in process and suitable for industrial large-scale production.

A novel process for synthesis of Rosuvastatin

A novel process for the preparation of antihypercholesterolemic drug rosuvastatin calcium using novel intermediates has been described. Novel intermediates have been characterized by using IR, NMR and Mass spectroscopy.

Method for preparing solid (4R-cis)-6-formyl-2,2-dimethyl-1,3-dioxane-4-tert-butyl acetate

The invention discloses a method for preparing solid (4R-cis)-6-formyl-2,2-dimethyl-1,3-dioxane-4-tert-butyl acetate and belongs to the pharmaceutical and chemical field. The method includes the following steps that a compound III is dissolved in a mixed solvent of methanol and water, potassium carbonate is added for hydrolysis, potassium carbonate is filtered out and removed, methanol is removed through distillation, an organic solvent is added, and an organic solvent solution of a compound II is obtained after washing; secondly, TEMPO, potassium bromide and sodium bicarbonate are added, stirred, mixed and cooled, then a sodium hypochlorite solution is added dropwise, stirring reaction is carried out, after reaction, a sodium thiosulfate solution is quenched, washed, dried and condensed, and a crude product of a compound I is obtained; thirdly, an organic solvent is added, cooled and stirred after being heated and dissolved and is crystallized and filtered to obtain solid crystal of the compound I. The preparation method is safe, environmentally friendly, easy and convenient to operate, high in yield, high in purify and capable of facilitating large-scale production.

A 2 - ((4R, 6S) - 6-formyl -2,2-di-substituted -1,3-dioxane-4-yl) ethyl ester preparation method

The invention relates to a simple and convenient preparation method of 2-((4R,6S)-6-formyl-2,2-disubstituted-1,3-dioxane-4-yl)acetate. The 2-((4R,6S)-6-formyl-2,2-disubstituted-1,3-dioxane-4-yl)acetate has a structure shown in a formula I. The preparation method comprises the following steps: by taking butadiene and 3,3-dialkyloxypropionate or 3-alkyloxyacrylate as raw materials, cyclizing under the catalysis of lewis acid to substitute benzaldehyde to form cyclic protection, then hydrolyzing and performing cyclization reaction with corresponding aldehyde (ketone) or dimethylacetal and diethylacetal thereof to prepare the 2-((4R,6S)-6-vinyl-2,2-disubstituted-1,3-dioxane-4-yl)acetate, and then preparing I through three-step reaction of vinyl ozonization. The preparation method is easily available in raw materials, and short in reaction process, a chiral center is constructed by utilizing the stabilization form of an equatorial bond of a hexatomic ring chair type structure, a flammable and combustible asymmetric reducer is not used, and the preparation method is simple and convenient and environment-friendly, and suitable for industrial production of chiral side chains of statins.

Stereoselective reduction of δ-hydroxy β-ketoesters to syndiol in achiral micellar system

A novel, efficient and stereo-selective process for synthesis of statin side chain, a key intermediate for statin type cholesterol lowering drugs such as Lipitor (atorvastatin) and Crestor (rosuvastatin) in achiral micellar media is reported. The key feature of this process is sodium borohydride reduction of δ-hydroxy β-ketoester in achiral micellar system in 92% de, thereby avoiding metal chelation methods which employ triakylborane, titanium (IV) isopropoxide or cerium (III) chloride prior to reduction.